Skip to main content

Advertisement

Table 1 Summary of key drug-drug interactions between HIV drugs and the licensed DAAs and dosing recommendations

From: Managing HIV/hepatitis C co-infection in the era of direct acting antivirals

  Telaprevir Boceprevir
ATV/r Monitoring for hyperbilirubinemia recommended Consider on a case by case basis if deemed necessary
DRV/r/, FPV/r LPV/r Not recommended Not recommended
EFV Increase TVR to 1,250 mg q8h Not recommended
ETR No dose adjustment needed No dose adjustment needed
RPV No dose adjustment needed No dose adjustment needed
RAL No dose adjustment needed No dose adjustment needed
TDF Increased monitoring is warranted No dose adjustment needed